- ContraFect Corporation CFRX shares are trading higher Thursday morning. However, there is no specific news to justify the move.
- Wednesday morning, ContraFect announced the dosing of the first patient in Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention procedure in patients with chronic prosthetic joint infections of the knee due to Staphylococcus aureus or Coagulase-Negative Staphylococci.
- The study was initiated earlier this month.
- ContraFect stock is gaining on heavy volume, with a session volume of 55 million shares traded, compared to the trailing 100-day volume of 3.08 million shares.
- According to data from Benzinga Pro, CFRX has a 52-week high of $362.4 and a 52-week low of $0.90.
- Price Action: CFRX shares are up 68.20% at $2.22 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
